Item 7.01 Regulation FD Disclosure.
As previously announced, King Pharmaceuticals, Inc. ("King") has entered into an amended and restated commitment letter (the "Commitment Letter"), pursuant to which Credit Suisse, Credit Suisse Securities (USA) LLC, Wachovia Bank, National Association, and Wachovia Capital Markets, LLC have committed to provide financing in connection with King's pending acquisition of Alpharma Inc. The Commitment Letter provides for a commitment by the lenders to provide debt financing of up to $775 million under senior secured credit facilities. King is also exploring, however, an alternative financing arrangement. This arrangement, if undertaken, could provide more favorable terms to King than the financing contemplated by the Commitment Letter. The alternative financing structure being considered would use King's existing revolving credit facility on amended terms, to provide up to $475 million in revolving loans, together with a new term facility in an aggregate principal amount of up to $300 million. King would expect that any such revolving facility and term facility would be fully secured by King's assets.
No alternative financing arrangements have yet been agreed to, and there is no assurance any will be entered into. Unless and until an alternative financing arrangement is entered into, King intends to proceed with the financing contemplated by the Commitment Letter.

---